Breaking News Instant updates and real-time market news.

BBBY

Bed Bath & Beyond

$17.21

-4.29 (-19.95%)

, DAL

Delta Air Lines

$52.98

1.51 (2.93%)

16:20
04/12/18
04/12
16:20
04/12/18
16:20

On The Fly: Top stock stories for Thursday

Stocks opened sharply higher and tacked on additional gains during the morning hours. Once the averages found a level, they drifted for the remainder of the session, albeit at higher levels as the day progressed. The strength was attributed to a lack of military action so far against Syria and the perception of a more strategic approach rather than an impulsive one. There was little else for investors to focus on as they prepare for the earnings season, which will begin tomorrow morning with some of the major banks reporting. ECONOMIC EVENTS: In the U.S., initial jobless claim fell 9,000 to 233,000 in the week ended April 7. Import prices were flat, with export prices 0.3% higher, in March. COMPANY NEWS: Shares of Bed Bath & Beyond (BBBY) finished 20% lower after the home goods retailer announced better than expected fourth quarter results but issued a weaker 2018 forecast. Following the news, several Wall Street analysts cut their price targets on the stock, while Raymond James analyst Beryl Bugatch downgraded Bed Bath & Beyond to Underperform, a sell-equivalent rating... Meanwhile, shares of airline operator Delta (DAL) gained nearly 3% after the company's earnings beat expectations despite revenue that fell short of the consensus forecast. MAJOR MOVERS: Among the notable gainers was Incyte (INCY), which gained 5% after UBS upgraded the stock to Buy from Neutral. Also higher was CB&I (CBI), which advanced 9% after the company reported better than expected preliminary Q1 results and McDermott (MDR) said its combination with the former is on track for the second quarter. Additionally, GoPro (GPRO) rose 7% after The Information's Alfred Lee reported that Chinese electronics maker Xiaomi has weighed whether to make a takeover offer to the action camera maker. Among the noteworthy losers was Apogee Enterprises (APOG), which dropped 9% after the company reported quarterly results and updated FY19 guidance. Also lower were shares of Mallinckrodt (MNK), which slid 7% following a report that a former associate director claimed in a whistleblower lawsuit that the company schemed "to misrepresent the actual clinical data concerning Acthar in order to alleviate the reimbursement hurdle by government payors to improperly increase Acthar sales." Following the news, Stifel analyst Annabel Saminy downgraded Mallinckrodt to Hold saying that while she cannot prove or disprove the alleged improper Acthar distribution and Medicare claims made against Mallinckrodt, she believes the "singularly persistent" overhang of Acthar will not lift in the near-term. INDEXES: The Dow gained 293.60, or 1.21%, to 24,483.05, the Nasdaq advanced 71.22, or 1.01%, to 7,140.25, and the S&P 500 rose 21.80, or 0.83%, to 2,663.99.

BBBY

Bed Bath & Beyond

$17.21

-4.29 (-19.95%)

DAL

Delta Air Lines

$52.98

1.51 (2.93%)

GPRO

GoPro

$5.22

0.35 (7.19%)

MNK

Mallinckrodt

$13.89

-1.01 (-6.78%)

INCY

Incyte

$69.83

3.54 (5.34%)

CBI

CB&I

$14.82

1.29 (9.53%)

APOG

Apogee Enterprises

$38.70

-3.76 (-8.86%)

  • 12

    Apr

  • 12

    Apr

  • 17

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 28

    Apr

  • 03

    May

  • 08

    May

  • 08

    May

  • 18

    May

  • 21

    May

  • 30

    May

  • 12

    Jun

  • 29

    Jun

  • 22

    Aug

BBBY Bed Bath & Beyond
$17.21

-4.29 (-19.95%)

04/12/18
04/12/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Paycom (PAYC) downgraded to Equal Weight from Overweight at Barclays with analyst Raimo Lenschow saying the stock has meaningfully outperformed over the last year while estimate revisions have been limited. 2. J.B. Hunt (JBHT) downgraded to Sector Weight from Overweight at KeyBanc. 3. Devon Energy (DVN) downgraded to Outperform from Focus List at Scotia Howard Weil. 4. PJT Partners (PJT) downgraded to Hold from Buy at Sandler O'Neill with analyst Sumeet Mody saying after appreciating 17% year-to-date, the stock is approaching fair value. 5. Bed Bath & Beyond (BBBY) downgraded to Underperform at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/12/18
LOOP
04/12/18
NO CHANGE
LOOP
Bed Bath & Beyond price target lowered to $18 from $23 at Loop
Loop Capital analyst Anthony Chukumba lowered his price target on Bed Bath & Beyond to $18 from $23 and maintained a Hold rating following the company's "much worse-than-expected" FY18 earnings guidance and subsequent sell-off.
04/12/18
RAJA
04/12/18
DOWNGRADE
RAJA
Underperform
Bed Bath & Beyond downgraded to Underperform at Raymond James
04/12/18
04/12/18
DOWNGRADE

Underperform
Bed Bath & Beyond downgraded to Underperform at Raymond James
As previously reported, Raymond James analyst Beryl Bugatch downgraded Bed Bath & Beyond to Underperform from Market Perform following quarterly results. Despite the array of initiatives announced by management, a key issue for the analyst is that the fleet of over 1,000 legacy Bed Bath & Beyond stores continue to deliver in-store mid-single-digit comp sales declines. Without some underlying growth in management generated earnings over the next two years, shareholder value is likely to erode further, he adds. Nonetheless, Bugatch points out that at its current valuation, Bed Bath may attract "activist" interest.
DAL Delta Air Lines
$52.98

1.51 (2.93%)

04/05/18
STFL
04/05/18
NO CHANGE
Target $100
STFL
Buy
Delta Air Lines price target raised to $100 from $90 at Stifel
Stifel analyst Joseph DeNardi raised his price target for Delta Air Lines to $100 from $90 on valuation. The analyst reiterates a Buy rating on the shares given Delta's combination of peer-leading operating margins, an investment grade balance sheet, structural advantages related to the location of its hubs and greater labor flexibility.
03/09/18
JPMS
03/09/18
NO CHANGE
JPMS
JPMorgan sees Airlines raising Q1 outlooks at next week's conference
JPMorgan analyst James Baker believes several Airlines will raise their Q1 guidance at his firm's Aviation, Transportation and Industrials Conference next week. He expects near-term consensus estimates to move higher for the airlines coming out of the presentations, particularly for United Continental (UAL). The analyst recommends increasing exposure to the sector ahead of the conference. He raised his estimates for United the most, taking his Q1 earnings per share forecast up to 32c from 3c. Other names in the space include American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU) and Southwest (LUV).
02/28/18
STFL
02/28/18
NO CHANGE
Target $90
STFL
Buy
Delta Air Lines price target raised to $90 from $85 at Stifel
Stifel analyst Joseph DeNardi raised his price target for Delta Air Lines to $90 after reviewing the company's annual filing. The price target represents a new high on the Street, according to Bloomberg. The analyst cites stronger growth from Delta's loyalty program for the target raise. His sum-of-the-parts analysis values the core airline at seven times 2019 earnings and the loyalty program at 22 times. DeNardi keeps a Buy rating on Delta Air Lines.
01/26/18
COWN
01/26/18
NO CHANGE
COWN
Airline sector weakness a buying opportunity, says Cowen
Cowen analyst Helane Becker noted airline stocks came under pressure as investors grew concerned about capacity growth by United Continental (UAL) and fears it would destroy the fare structure. The analyst noted the capacity growth is in small markets where they might make a difference but that RASM is up year-over-year. Becker would be a buyer of Alaska Air (ALK), Delta Air (DAL), American Airlines (AAL) and Southwest Air (LUV) on the pullback, but would avoid United Continental shares.
GPRO GoPro
$5.22

0.35 (7.19%)

01/23/18
01/23/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Netflix (NFLX) downgraded to Neutral from Buy at Buckingham with analyst Matthew Harrigan citing valuation. 2. GoPro (GPRO) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Yuuji Anderson arguing that the market is giving too much credit to the company for its strategic value. 3. Wayfair (W) downgraded to Hold from Buy at Stifel with analyst Scott Devitt citing his view that the risk/reward is balanced at the stock's current levels. 4. Fortinet (FTNT) downgraded to Hold from Buy at Deutsche Bank with analyst Gray Powell saying his field discussions indicate the company's growth in the fourth quarter was weaker than expected. 5. Sprint (S) downgraded to Underperform from Neutral at Macquarie with analyst Amy Young saying she believes Sprint is stuck between a slowdown in the multi-year turnaround and a lack of near-term strategic options as circumstances have deteriorated with rising competition, executive turnover, and increasing capital expenditures. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/02/18
JPMS
02/02/18
DOWNGRADE
Target $8
JPMS
Neutral
GoPro downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Paul Coster downgraded GoPro to Neutral and lowered his price target for the shares to $8 from $9. The analyst sees a tough first half of 2018 for the company after its Q4 results missed expectations. GoPro has not made the ease-of-use breakthrough that will drive growth, and the product cycle in the second half of 2018 will likely only deliver incremental improvement in the experience, Coster tells investors in a research note. He lowered his estimates and moves to an enterprise value-to-sales valuation approach given the absence of profitability.
02/02/18
SBSH
02/02/18
NO CHANGE
Target $5.5
SBSH
Neutral
GoPro price target lowered to $5.50 from $7 at Citi
Citi analyst Stanley Kovler lowered his price target for GoPro to $5.50 following the company's weaker than expected Q4 results. The analyst expects GoPro's 2018 to be second-half weighted for the third consecutive year as it once again burns off excess inventory in the first half. Kovler keeps a Neutral rating on the shares.
01/23/18
01/23/18
DOWNGRADE
Target $5

Underweight
GoPro downgraded to Underweight on limited strategic value at Morgan Stanley
As previously reported, Morgan Stanley Yuuji Anderson downgraded GoPro to Underweight from Equal Weight, arguing that the market is giving too much credit to the company for its strategic value. Improving action camera demand hinges on meaningful improvements in usability, and without acceleration in that area Yuuji thinks negative trends are more likely to continue into 2019, weighing on earnings and GoPro's potential strategic value, he tells investors in a note partially titled "A Long Year Ahead." The analyst cut his price target on GoPro to $5 from $9.50.
MNK Mallinckrodt
$13.89

-1.01 (-6.78%)

04/12/18
WELS
04/12/18
NO CHANGE
WELS
Market Perform
Wells says suit against Salix may have been filed by Mallinckrodt whistleblower
Wells Fargo analyst David Maris said he found reference to a lawsuit filed by a Rasivinder Dhaliwal against Salix Pharmaceuticals in January 2015, thought he has not been able to confirm that this Rasivinder Dhaliwal is the same one who filed a recent whistleblower lawsuit against Mallinckrodt (MNK). Maris previously stated in a note to investors earlier today that Mallinckrodt strongly disagrees with the allegations, believes the suit is baseless, and plans to defend itself vigorously. The Fly notes that Valeant (VRX) acquired Salix in 2015.
04/12/18
WELS
04/12/18
NO CHANGE
WELS
Market Perform
Mallinckrodt strongly disagrees with whistleblower suit, says Wells Fargo
Mallinckrodt shares are down sharply after news of a whistleblower lawsuit was made public, Wells Fargo analyst David Maris tells investors in an intraday research note. Mallinckrodt strongly disagrees with the allegations, believes the suit is baseless, and plans to defend itself vigorously, Maris writes after speaking to the company. The analyst believes whistleblower suits and court documents "often read poorly for a company as they are often one sided." However, the complaint alleges a number of bad actions by Mallinckrodt that could have larger implications if true, Maris adds. He recommends not jumping to conclusions and keeps a Market Perform rating on Mallinckrodt. The stock in morning trading is down 7% to $13.84.
04/12/18
STFL
04/12/18
DOWNGRADE
STFL
Hold
Mallinckrodt downgraded to Hold from Buy at Stifel
04/12/18
04/12/18
DOWNGRADE
Target $15

Hold
Stifel downgrades Mallinckrodt to Hold with sentiment seen staying low
As previously reported, Stifel analyst Annabel Samimy downgraded Mallinckrodt to Hold from Buy. Samimy said he cannot prove or disprove the alleged improper Acthar distribution and Medicare claims made against Mallinckrodt in a recently filed whistleblower lawsuit, but he believes that the "singularly persistent" overhang of Acthar will not lift in the near-term, regardless of the strength of the company's upcoming pipeline opportunities. The analyst thinks it is prudent to step to the side until the Acthar overhang, coupled with the overhang of opioid litigation, has more clarity toward resolution, he tells investors. Samimy lowered his price target on Mallinckrodt shares to $15 from $50.
INCY Incyte
$69.83

3.54 (5.34%)

04/12/18
04/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Incyte (INCY) upgraded to Buy from Neutral at UBS with analyst Carter Gould saying the stock offers an improved risk/reward profile after resetting lower on negative epacadostat Phase 3 data and removal of the drug from analyst models. 2. TechnipFMC (FTI) upgraded to Buy from Neutral at Goldman Sachs with analyst Waqar Syed saying while his 2018/2019 EBITDA estimates are little changed, his 2020 EBITDA estimates have been raised nearly 18% owing to expectations for higher inbound orders in 2019 for the Subsea and Onshore/Offshore segments. 3. Prologis (PLD) upgraded to Buy from Hold at Jefferies with analyst Jonathan Petersen saying he sees the company posting one of the strongest levels of internal growth among the blue-chip real estate investment trusts in 2018. 4. Mylan (MYL) upgraded to Outperform from Market Perform at Leerink with analyst Ami Fadia citing valuation disconnect given the diversified business and catalyst path. 5. Summit Hotel Properties (INN) upgraded to Buy from Underperform at BofA/Merrill with analyst Shaun Kelley citing relative valuation, its potential to outperform peers on the top-line in an accelerating RevPAR environment, and lower relative cost pressure given a lower proportion of labor costs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/09/18
04/09/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Westlake Chemical (WLK) downgraded to Neutral from Overweight at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 2. Mettler-Toledo (MTD) downgraded to Neutral from Buy at Goldman Sachs with analyst Patrick Donnelly saying he sees an attractive fundamental backdrop across Tools but is more cautious on the outlook for sales upside at Mettler given his view of a likely moderation of growth in China after a year of catch-up investment in the region. Donnelly also highlights "tough comps" in Labs and Product inspection. 3. Franklin Resources (BEN) downgraded to Neutral from Buy at BofA/Merrill with analyst Michael Carrier saying Franklin's bottom half performance and continued outflows limits organic growth and multiple expansion. 4. NewLink Genetics (NLNK) downgraded to Neutral from Overweight at Cantor Fitzgerald and Baird as well as to Hold from Buy at Jefferies. 5. Incyte (INCY) downgraded to Hold from Buy at Gabelli with analyst Jing He citing the "surprising" failure of the Phase 3 ECHO-301 study in melanoma. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/18
MZHO
04/10/18
NO CHANGE
Target $27
MZHO
Buy
Concert still likely to win IPR challenge against Incyte, says Mizuho
Mizuho analyst Difei Yang does not see a read-through to the final decision from the Patent Trial and Appeal Board's granting Incyte's (INCY) motion for reconsideration as it relates to the Inter Partes Review Petition challenge against Concert Pharmaceuticals (CNCE). The analyst still thinks Concert is likely to win the challenge based on how it has defended its patents historically. The company has an "impressive track record" on intellectual protection front, Yang tells investors in a research note. The analyst reiterates a Buy rating on Concert Pharmaceuticals with a $27 price target. The stock in morning trading is down 5%, or 96c, to $19.08.
04/12/18
UBSW
04/12/18
UPGRADE
Target $76
UBSW
Buy
Incyte upgraded to Buy from Neutral at UBS
UBS analyst Carter Gould upgraded Incyte (INCY) to Buy while lowering his price target for the shares to $76 from $106. The stock offers an improved risk/reward profile after resetting lower on negative epacadostat Phase 3 data and removal of the drug from analyst models, Gould tells investors in a research note. The focus on epacadostat "obscured an otherwise solid, profitable, and strategically attractive Jakafi franchise," the analyst contends. He believes the base business alone supports $65 per share, even before considering its "compelling strategic attractiveness." Incyte closed yesterday down $1.83 to $66.29. Gould thinks clinical catalysts against low expectations can drive $13-$17 per share of upside over 2018.
CBI CB&I
$14.82

1.29 (9.53%)

01/24/18
KEYB
01/24/18
UPGRADE
Target $14
KEYB
Overweight
McDermott upgraded to Overweight with $14 target at KeyBanc
KeyBanc analyst Tahira Afzal upgraded McDermott (MDR) to Overweight from Sector Weight with a $14 price target. The analyst expects a "step-up in execution" at CB&I (CBI) following the merger and has confidence in a sustained improvement in the energy macro environment. He believes the deal will create value.
12/20/17
MSCO
12/20/17
NO CHANGE
MSCO
Underweight
McDermott may have hard time recognizing CB&I synergies, says Morgan Stanley
Morgan Stanley analyst Ole Slorer said he sees room for concern over McDermott's (MDR) deal to combine in an all-stock transaction with CB&I (CBI). McDermott's "pristine" balance sheet and improved execution could be hurt by CBI's recent execution challenges and "higher than optimal" debt, while synergies from the merger may be difficult to realize, contends Slorer, who keeps an Underweight rating on McDermott shares.
12/19/17
MACQ
12/19/17
UPGRADE
MACQ
Neutral
CB&I upgraded to Neutral from Underperform at Macquarie
CBI (CBI) is being acquired by McDermott International (MDR).
12/19/17
DADA
12/19/17
DOWNGRADE
Target $19
DADA
Neutral
CB&I downgraded to Neutral from Buy at DA Davidson
DA Davidson analyst Brent Thielman downgraded CB&I (CBI) to Neutral from Buy and lowered his price target to $19 from $25 after the company entered into a merger agreement with McDermott International (MDR). Thielman says that CB&I's execution challenges reduce the likelihood of a competitive bid, adding that he expects the deal to pass regulatory requirements.
APOG Apogee Enterprises
$38.70

-3.76 (-8.86%)

04/04/18
GSCO
04/04/18
DOWNGRADE
Target $39
GSCO
Sell
Apogee Enterprises downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Samuel Eisner downgraded Apogee Enterprises to Sell and cut his price target for the shares to $39 from $44. The analyst believes "cyclical maturity" and margin risk warrant caution on the shares. Goldman expects private non-residential construction growth to flatten in 2018 and 2019, which makes Apogee's returns outlook less attractive relative to peers, Eisner tells investors in a research note.
08/24/17
DADA
08/24/17
NO CHANGE
DADA
Apogee Enterprises weakness overdone, says DA Davidson
DA Davidson analyst Brent Thielman says that the reduction in Apogee's fiscal 2018 guidance "raises concerns" about its "M&A and mid-size glass market penetration strategies." However, the analyst thinks that the weakness in the stock was overdone, and he remains upbeat on the company's fiscal 2019 outlook. The analyst cut his price target on the stock to $52 from $65 but keeps a Buy rating on the shares.
05/25/17
SIDC
05/25/17
INITIATION
SIDC
Buy
Apogee Enterprises re-initiated with a Buy at Sidoti
04/17/17
CHLM
04/17/17
NO CHANGE
Target $68
CHLM
Buy
Apogee Enterprises pullback creates buying opportunity, says Craig-Hallum
Craig-Hallum analyst Eric Stine notes that Apogee Enterprises reported "solid 4Q results," but points out that the pullback on misplaced concerns over non-re construction cycle due to 2018 revenue guidance creates a buying opportunity. The analyst reiterates a Buy rating and $68 price target.

TODAY'S FREE FLY STORIES

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

, PCG

PG&E

$42.98

2.44 (6.02%)

18:17
06/22/18
06/22
18:17
06/22/18
18:17
Hot Stocks
Northwest Natural to sell Gill Ranch Storage to SENSA Holdings »

NW Natural (NWN)…

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

PCG

PG&E

$42.98

2.44 (6.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ORLY

O'Reilly Automotive

$285.90

-1.18 (-0.41%)

18:03
06/22/18
06/22
18:03
06/22/18
18:03
Hot Stocks
O'Reilly Automotive's O'Reilly sells 19,250 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

$33.15

0.02 (0.06%)

17:46
06/22/18
06/22
17:46
06/22/18
17:46
Hot Stocks
South Jersey Industries announces approval of Elizabethtown Gas purchase »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAAS

AquaVenture

$15.36

0.12 (0.79%)

17:27
06/22/18
06/22
17:27
06/22/18
17:27
Hot Stocks
AquaVenture extends long-stop date for Ghana plant acquisition to September 30 »

AquaVenture announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Periodicals
Nissan chooses Thailand for hybrid's first export market, Nikkei reports »

Nissan has planned to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROV

Trovagene

$0.81

-0.0068 (-0.83%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Hot Stocks
Trovagene CEO William Welch resigns, Dr. Thomas Adams named interim CEO »

Trovagene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$3.26

0.005 (0.15%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$33.49

-0.15 (-0.45%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Hot Stocks
Aecom to compete for $148.5M U.S. Army contract »

AECOM-Baker JV, Bryan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:17
06/22/18
06/22
17:17
06/22/18
17:17
Hot Stocks
Lockheed Martin awarded $175.3M U.S. Navy contract modification »

Lockheed Martin is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:16
06/22/18
06/22
17:16
06/22/18
17:16
Hot Stocks
Lockheed Martin awarded $1.12B U.S. Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

XLE

Energy Select Sector SPDR

$75.21

1.59 (2.16%)

, XLU

Utilities SPDR

$50.75

0.36 (0.71%)

17:14
06/22/18
06/22
17:14
06/22/18
17:14
General news
Week ending ETF Scorecard: Utilities and Real Estate advance, Industrials slump »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$75.21

1.59 (2.16%)

XLU

Utilities SPDR

$50.75

0.36 (0.71%)

IYR

DJ US Real Estate Index Fund

$80.69

0.56 (0.70%)

XLP

Consumer Staples Sector SPDR

$51.62

0.42 (0.82%)

XLY

Consumer Discretionary Sector SPDR

$111.34

-0.15 (-0.13%)

XLB

S&P Select Materials SPDR

$58.49

0.79 (1.37%)

XLF

Financial Select Sector

$27.07

-0.145 (-0.53%)

XLV

Health Care Select Sector SPDR

$84.91

0.35 (0.41%)

XLK

Technology Select Sector SPDR

$70.78

-0.24 (-0.34%)

XLI

Industrial Select Sector SPDR

$72.59

0.22 (0.30%)

GLD

SPDR Gold Trust

$120.33

0.27 (0.22%)

SLV

iShares Silver Trust

$15.49

0.135 (0.88%)

USO

United States Oil Fund

$14.02

0.71 (5.33%)

UNG

United States Natural Gas Fund

$23.87

-0.24 (-1.00%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.91

-0.015 (-0.02%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$113.99

0.105 (0.09%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.57

0.06 (0.05%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.11

0.03 (0.03%)

SHY

iShares 1-3 Year Treasury Bond

$83.30

0.005 (0.01%)

IWD

iShares Russell 1000 Value

$122.51

0.56 (0.46%)

IWF

iShares Russell 1000 Growth

$146.24

-0.2 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFNX

Pfenex

$5.43

0.14 (2.65%)

17:01
06/22/18
06/22
17:01
06/22/18
17:01
Hot Stocks
Pfenex set to join Russell 2000 Index »

Pfenex announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXE

Bellatrix Exploration

$1.00

-0.0101 (-1.00%)

17:01
06/22/18
06/22
17:01
06/22/18
17:01
Syndicate
Breaking Syndicate news story on Bellatrix Exploration »

Bellatrix Exploration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGI

Logitech

$44.24

0.25 (0.57%)

16:56
06/22/18
06/22
16:56
06/22/18
16:56
Initiation
Logitech initiated  »

Logitech initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$30.35

0.925 (3.14%)

16:51
06/22/18
06/22
16:51
06/22/18
16:51
Hot Stocks
Breaking Hot Stocks news story on PagSeguro Digital »

Point72 Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

APLS

Apellis

$21.75

-0.2 (-0.91%)

16:50
06/22/18
06/22
16:50
06/22/18
16:50
Conference/Events
Apellis to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$274.75

0.47 (0.17%)

16:50
06/22/18
06/22
16:50
06/22/18
16:50
Periodicals
SEC investigates whether companies rounded up earnings, WSJ reports »

The U.S. Securites and…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$274.75

0.47 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THRM

Gentherm

$38.20

-0.75 (-1.93%)

16:45
06/22/18
06/22
16:45
06/22/18
16:45
Conference/Events
Gentherm to hold a strategic update »

Strategic Update for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGTX

MeiraGTx

$11.86

-0.97 (-7.56%)

16:43
06/22/18
06/22
16:43
06/22/18
16:43
Hot Stocks
Breaking Hot Stocks news story on MeiraGTx »

Perceptive Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$86.80

0.51 (0.59%)

16:39
06/22/18
06/22
16:39
06/22/18
16:39
Conference/Events
Medtronic to hold an analyst and investor briefing »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

, FOX

21st Century Fox

$48.28

0.31 (0.65%)

16:35
06/22/18
06/22
16:35
06/22/18
16:35
Hot Stocks
21st Century Fox extends CFO John Nallen's employment contract to 2021 »

On June 22, 21st Century…

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

FOX

21st Century Fox

$48.28

0.31 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$10.97

0.5 (4.78%)

16:34
06/22/18
06/22
16:34
06/22/18
16:34
Hot Stocks
Breaking Hot Stocks news story on Fennec »

Opaleye Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBBP

Strongbridge Biopharma

$6.20

-0.15 (-2.36%)

16:33
06/22/18
06/22
16:33
06/22/18
16:33
Hot Stocks
Breaking Hot Stocks news story on Strongbridge Biopharma »

Opaleye Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

16:30
06/22/18
06/22
16:30
06/22/18
16:30
Options
Preliminary option volume of 16.8M today »

Preliminary option volume…

COOL

PolarityTE

$38.91

-0.09 (-0.23%)

16:28
06/22/18
06/22
16:28
06/22/18
16:28
Conference/Events
PolarityTE to hold a meeting »

Management hosts a Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.